InvestLog
Back to Market返回行情

AEON AEON Biopharma, Inc.

AMEXHealthcare
$0.5001-0.52%OpenMarket Cap: $5.9M

As of 2026-07-10 14:09

Why AEON matters now

AEON Biopharma, Inc. (AEON) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.50 with -0.52% on the session and $5.9M in market capitalization.

The latest indexable market news headline is "AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society" from GlobeNewsWire.

Latest News

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache SocietyGlobeNewsWire · 2026-06-04
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire · 2026-05-14
AEON Biopharma Sets Annual Shareholder MeetingGlobe News Wire · 2026-04-24
AEON Biopharma Sets Annual Shareholder MeetingGlobeNewsWire · 2026-04-24
Aerovate Therapeutics (NASDAQ:AVTE) & AEON Biopharma (NASDAQ:AEON) Head to Head SurveyDefense World · 2026-04-13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

AMEX

Beta

0.61

AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.